ClinicalTrials.gg
CompletedNCT05403125Updated Sep 17, 2025

SDF Application in Oral Cancer Patients to Prevent Dental Caries

An Early Phase 1 interventional study of silver diamine fluoride, 38% and Sodium fluoride gel, 5000 PPM in Dental Caries, sponsored by Texas A & M University Baylor College Of Dentistry. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Texas A & M University Baylor College Of Dentistry · Early Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.
Phase
Early Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The Texas A \& M College of Dentistry, with partner Texas Oncology-Baylor Charles A. Sammons Cancer-Center Radiation-Oncology, proposes to conduct a preliminary clinical study (NIH Stage 0) to pilot test a randomized clinical trial of the efficacy of professionally applied 38% silver diamine fluoride to prevent tooth decay in 60 patients who are being treated with radiation for life threatening head and neck cancer.

Read the detailed description

Head and neck cancer has increased in Texas over the last two decades. Radiation-induced tooth decay is a devastating yet potentially preventable side effect of the cancer treatment. Silver diamine fluoride, already the standard of care in children, is inexpensive, easy to apply, and safe. The objective of the research is to conduct a single site pilot RCT (NIH Stage 0) to determine feasibility and preliminarily assess the efficacy of 38% silver diamine fluoride and 5000 PPM fluoride gel for prevention of radiation-induced dental caries over 6 months. Eligible participants will be up to 60 head and neck cancer patients who are scheduled for radiotherapy. The proposed intervention will be applied within 1 m before and at 1- and 3-m post radiation. The primary outcome is dental caries surfaces at 6 months post-radiotherapy (DMFS).Secondary outcomes are The Gingival Index, Gingival Bleeding Index, MDASI-HN, and Oral Health Quality of Life score will be secondary outcomes.

02

Conditions studied

  • Dental Caries

Keywords

  • Oral and Pharyngeal Cancer
  • Xerostomia
  • Silver diamine fluoride
  • Sodium fluoride gel 5000 PPM
03

In context

Dental Caries

1,171 studies on the registry are indexed under Dental Caries; 209 are open to participants now.

This study's enrollment of 56 is close to the median of 60 across 967 interventional studies indexed under Dental Caries.

Browse Dental Caries studies →

Lead sponsor

Texas A & M University Baylor College Of Dentistry is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Head and Neck cancer

Exclusion criteria

Exclusion Criteria:

  • Prognosis less than 1 year
  • Radiation field of treatment does not involve jaws
05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Package

    Topical application of 38% silver diamine fluoride plus 5000 PPM fluoride gel 1 mo before and 1 and 3 months after radiation treatment

    Device: silver diamine fluoride, 38% · Device: Sodium fluoride gel, 5000 PPM

  • Active comparator
    Gel Alone

    Placebo application of silver diamine fluoride plus 5000 PPM fluoride gel 1 mo before and 1 and 3 months after radiation treatment

    Device: Sodium fluoride gel, 5000 PPM

Interventions

  • Devicesilver diamine fluoride, 38%

    Topical application to all surfaces of the teeth

    Also known as: Advantage Silver Dental Arrest

  • DeviceSodium fluoride gel, 5000 PPM

    Gel applied after application of silver diamine fluoride and dispensed for home use

    Also known as: Elevate FluoriMax 5000R

06

What researchers measure

Primary outcomes

  1. Dental Caries (DMFS)

    Dental Caries Surfaces determined by intraoral inspection

    Time frame: 6 months

Secondary outcomes

  1. Gingival Index

    Silness and Loe Gingival Index for assessment of gingival condition (0 to 3) determined clinically

    Time frame: 6 months

  2. Bleeding Index

    Bleeding at 6 sites of each tooth determined clinically

    Time frame: 6 months

  3. Oral Health Quality of Life

    Questionnaire

    Time frame: 6 months

  4. MD Anderson Symptom Inventory-Head and Neck

    Questionnaire

    Time frame: 6 months

07

Study locations

1 site
  • Baylor College of Dentistry
    Dallas, Texas 75246, United States
08

References and documents

Publications

  • Noureldin AAK, Sones A, Mendoza L, Mancl L, Milgrom P. Effectiveness of silver diamine fluoride in preventing radiation-induced caries: A pilot study. J Am Dent Assoc. 2026 Jul 16:S0002-8177(26)00340-5. doi: 10.1016/j.adaj.2026.05.008. Online ahead of print. PubMed 42461172 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Aug 2023, 14 months.

Of 15 phase 1 interventional studies under Dental Caries, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 18. This study's 14 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2022
First posted
Jun 3, 2022
StartActual
May 20, 2022
Primary completionActual
Aug 11, 2023
CompletionActual
Mar 18, 2025
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05403125
Lead sponsor
Texas A & M University Baylor College Of Dentistry
Responsible party
Amal Noureldin (Clinical Associate Professor, Texas A & M University Baylor College Of Dentistry) — Principal investigator
First posted
Jun 3, 2022
Start date
May 20, 2022
Primary completion
Aug 11, 2023
Completion
Mar 18, 2025
Last update
Sep 17, 2025

Study contacts

Amal Noureldin, DDS
principal investigator · TAMU Baylor College of Dentistry

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion